← Evidence map

ArticleBiologics : targets & therapy2025

Efficacy, Safety, and Cost-Effectiveness of the Infliximab Biosimilar GP-1111 in Patients with Inflammatory Bowel Disease Who Underwent a Nonmedical Switch: A Prospective Cohort Study.

Máté Pápista et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Efficacy, Safety, and Cost-Effectiveness of the Infliximab Biosimilar GP-1111 in Patients with Inflammatory Bowel Disease Who Underwent a Nonmedical Switch: A Prospective Cohort Study. | OpenQuestion